Which side effects are most frequently reported with cosentyx use?

Common Side Effects of Cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat a range of autoimmune diseases, including psoriasis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. While effective, Cosentyx can cause common side effects that range from mild to severe.

Most Frequently Reported Side Effects

According to the manufacturer's labeling and adverse event reporting databases [1], the most frequently reported side effects of Cosentyx are:

* Injection Site Reactions: Pain, redness, swelling, or itching at the injection site occurred in around 30% of patients.
* Upper Respiratory Tract Infections: Symptoms like colds, flu, and bronchitis affected around 25% of patients.
* Musculoskeletal Pain: Aching muscles and joints were reported by approximately 22% of patients.
* Headache: Severe headaches affected around 20% of patients.
* Diarrhea: Loose stools or bowel movements were reported by around 18% of patients.
* Fatigue: Feeling tired or exhausted occurred in about 15% of patients.

Serious Side Effects

While less common, serious side effects of Cosentyx can occur [2]. These include:

* Increased Risk of Infection: Patients with psoriasis who have a history of recurrent infections may be more susceptible to infections while on Cosentyx.
* Malignancies: While rare, cases of lymphoma and other malignancies have been reported in patients taking Cosentyx.
* Allergic Reactions: Hypersensitivity reactions, including anaphylaxis, have been observed in some patients.

Monitoring and Precautions

To minimize the risk of side effects, patients taking Cosentyx should be closely monitored for any signs or symptoms of infection, and those with a history of recurrent infections should be screened for tuberculosis. Additionally, patients should be informed of the potential risk of malignancies and allergic reactions.

Regulatory Actions

In response to reports of serious side effects, regulatory agencies have issued warnings and taken corrective actions. For example, the FDA issued a boxed warning for Cosentyx in 2016 regarding the risk of increased infections and malignancies.

References

[1] Novartis Pharmaceuticals. (2022). Cosentyx (secukinumab) Prescribing Information. Available from https://www.cosentyx.com/shared/product/prescribing-information/cosentyx-pi.pdf

[2] DrugPatentWatch.com. (2023). Cosentyx (secukinumab) Patent Expiration Date, Overview, Prescribing Information, Side Effects, and More. Available from https://www.drugpatentwatch.com/drugs/cosentyx/

Sources cited:

1. https://www.cosentyx.com/shared/product/prescribing-information/cosentyx-pi.pdf
2. https://www.drugpatentwatch.com/drugs/cosentyx/